Niemann Pick Disease Type C Market, By Drug (Pipeline Drugs (Arimoclomol and Trappsol Cyclo), and Marketed Drugs (Miglustat (Zavesca))), By Indication (Niemann-Pick Disease Type C1 and Niemann-Pick Disease Type C2), By Distribution Channel (Hospital Pharm

Niemann Pick Disease Type C Market, By Drug (Pipeline Drugs (Arimoclomol and Trappsol Cyclo), and Marketed Drugs (Miglustat (Zavesca))), By Indication (Niemann-Pick Disease Type C1 and Niemann-Pick Disease Type C2), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, and Rest Of World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Niemann-Pick disease type C (NPC) is a rare genetic disorder that is a type of lysosomal storage disorder. NPC leads to accumulation of cholesterol and other fatty substances in different tissues of the body, such as brain and others. The onset of specific symptoms for NPC varies from person to person. In most cases, the symptoms appear in the childhood, which progresses to cause life-threatening complications with increasing age. NPC occurs as a result of mutations in the NPC 1 gene and NPC 2 gene, which is inherited in an autosomal recessive manner.
Market Dynamics
Market players are receiving approvals from regulatory authorities, which is one of the important steps for launching products in the market. This is expected to drive growth of the global Niemann-Pick disease type C treatment market over the forecast period. For instance, in May 2020, Cyclo Therapeutics, Inc., a clinical stage biotechnology company announced that it has received positive feedback from European Medicines Agency on its pivotal trial design for trappsol cyclo for the treatment of Niemann-Pick Disease Type C1.
Key features of the study:
This report provides in-depth analysis of the global Niemann pick disease type C market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Niemann pick disease type C market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Orphazyme A/S, Cyclo Therapeutics, Inc., and Johnson & Johnson
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global Niemann pick disease type C market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Niemann pick disease type C market
Detailed Segmentation:
Global Niemann Pick Disease Type C Market, By Drug:
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
Global Niemann Pick Disease Type C Market, By Indication:
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
Global Niemann Pick Disease Type C Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Global Niemann Pick Disease Type C Market, By Region:
North America
By Drug
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
By Indication
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
By Country
U.S.
Canada
Latin America
By Drug
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
By Indication
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
By Indication
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
By Indication
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Rest Of World
By Drug
Pipeline Drugs
Arimoclomol
Trappsol Cyclo
Marketed Drugs
Miglustat (Zavesca)
By Indication
Niemann-Pick Disease Type C1
Niemann-Pick Disease Type C2
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
By Country
Israel
Iran
Other Countries
Company Profiles
Orphazyme A/S *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Cyclo Therapeutics, Inc.
Johnson & Johnson
“*” marked represents similar segmentation in other categories in the respective section.